Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval

Yusimry Biosimilar To Humira Set For 1 July 2023 Launch, After Multiple Rivals

 
• By David Wallace
  
Alarm clock dollar bills money
Coherus must wait until mid-2023 to make its “compelling value proposition” • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products